The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis

From the University of Nebraska Medical Center, Omaha, NE; FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS. Partial funding for this study came from Pfizer through the ASPIRE competitive grant program – no one from Pfizer had input on the final manuscript. Dr. Michaud received additional research grant funding from the Rheumatology Research Foundation. Address correspondence to Kaleb Michaud, 986270 Nebraska Medical Center, Omaha, NE 68198. kmichaud{at}unmc.edu

From the University of Nebraska Medical Center, Omaha, NE; FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS. Partial funding for this study came from Pfizer through the ASPIRE competitive grant program – no one from Pfizer had input on the final manuscript. Dr. Michaud received additional research grant funding from the Rheumatology Research Foundation. Address correspondence to Kaleb Michaud, 986270 Nebraska Medical Center, Omaha, NE 68198. kmichaud{at}unmc.edu

From the University of Nebraska Medical Center, Omaha, NE; FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS. Partial funding for this study came from Pfizer through the ASPIRE competitive grant program – no one from Pfizer had input on the final manuscript. Dr. Michaud received additional research grant funding from the Rheumatology Research Foundation. Address correspondence to Kaleb Michaud, 986270 Nebraska Medical Center, Omaha, NE 68198. kmichaud{at}unmc.edu